REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024. The event will take place in New York, NY, featuring a fireside chat at 8:30 a.m. ET.
Investors and interested parties can access a live webcast of the fireside chat through the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation, allowing those unable to attend the live event to catch up on the discussion.
This conference participation highlights REGENXBIO's ongoing engagement with the investment community and its commitment to sharing insights into its work in the field of genetic medicines.
REGENXBIO Inc. (Nasdaq: RGNX) ha annunciato la sua partecipazione alla 8ª Conferenza Annuale sui Farmaci Genetici di Chardan che si terrà lunedì 30 settembre 2024. L'evento si svolgerà a New York, NY, con un colloquio informale alle 8:30 a.m. ET.
Investitori e parti interessate possono accedere a un webcast dal vivo del colloquio informale attraverso la sezione Investitori del sito web di REGENXBIO all'indirizzo www.regenxbio.com. Una registrazione archiviata del webcast sarà disponibile per circa 30 giorni dopo la presentazione, permettendo a coloro che non possono partecipare all'evento dal vivo di recuperare i contenuti della discussione.
Questa partecipazione alla conferenza sottolinea il continuo impegno di REGENXBIO con la comunità degli investitori e la sua volontà di condividere approfondimenti sul proprio lavoro nel campo dei farmaci genetici.
REGENXBIO Inc. (Nasdaq: RGNX) ha anunciado su participación en la 8va Conferencia Anual de Medicinas Genéticas de Chardan el lunes 30 de septiembre de 2024. El evento se llevará a cabo en Nueva York, NY, con una charla informal a las 8:30 a.m. ET.
Los inversores y las partes interesadas pueden acceder a un webcast en vivo de la charla informal a través de la sección de Inversores del sitio web de REGENXBIO en www.regenxbio.com. Un replay archivado del webcast estará disponible durante aproximadamente 30 días después de la presentación, permitiendo a quienes no puedan asistir al evento en vivo ponerse al día con la discusión.
Esta participación en la conferencia resalta el compromiso continuo de REGENXBIO con la comunidad de inversores y su dedicación a compartir conocimientos sobre su trabajo en el campo de las medicinas genéticas.
REGENXBIO Inc. (Nasdaq: RGNX)는 Chardan의 제8회 연례 유전자 의약품 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 30일 월요일에 뉴욕, NY에서 열리며, 오전 8시 30분 ET에 파이어사이드 채팅이 있을 예정입니다.
투자자와 관심 있는 당사자는 www.regenxbio.com의 REGENXBIO 웹사이트 투자자 섹션을 통해 실시간 웹캐스트에 접속할 수 있습니다. 발표 후 약 30일 동안 아카이브 다시보기가 제공되어, 라이브 이벤트에 참석하지 못한 사람들도 논의를 확인할 수 있습니다.
이번 컨퍼런스 참여는 REGENXBIO가 투자 커뮤니티와 지속적으로 소통하고 있으며, 유전자 의약품 분야에서의 활동에 대한 통찰을 공유하고자 하는 의지를 강조합니다.
REGENXBIO Inc. (Nasdaq: RGNX) a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan, qui se tiendra le lundi 30 septembre 2024. L'événement aura lieu à New York, NY, avec une discussion informelle à 8h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la discussion informelle via la section Investisseurs du site Web de REGENXBIO à l'adresse www.regenxbio.com. Un replay archivé du webinaire sera disponible pendant environ 30 jours après la présentation, permettant à ceux qui ne peuvent pas assister à l'événement en direct de rattraper la discussion.
Cette participation à la conférence souligne l'engagement continu de REGENXBIO envers la communauté des investisseurs et son engagement à partager des informations sur son travail dans le domaine des médicaments génétiques.
REGENXBIO Inc. (Nasdaq: RGNX) hat seine Teilnahme an der 8. jährlichen Konferenz für genetische Medikamente von Chardan am Montag, den 30. September 2024 bekannt gegeben. Die Veranstaltung findet in New York, NY statt und umfasst ein informelles Gespräch um 8:30 Uhr ET.
Investoren und Interessierte können über den Investorenbereich der REGENXBIO-Website unter www.regenxbio.com auf einen Live-Webcast des informellen Gesprächs zugreifen. Eine archivierte Wiederholung des Webcasts wird etwa 30 Tage nach der Präsentation verfügbar sein, damit diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, die Diskussion nachholen können.
Diese Konferenzteilnahme unterstreicht das kontinuierliche Engagement von REGENXBIO gegenüber der Investoren-Community und das Bestreben, Einblicke in seine Arbeit im Bereich der genetischen Medikamente zu teilen.
- None.
- None.
Chardan's 8th Annual Genetic Medicines Conference
Fireside Chat: Monday, September 30, 2024 at 8:30 a.m. ET
Location:
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-chardans-8th-annual-genetic-medicines-conference-302255684.html
SOURCE REGENXBIO Inc.
FAQ
When and where is REGENXBIO (RGNX) participating in Chardan's Genetic Medicines Conference?
What time is REGENXBIO's (RGNX) fireside chat at the Chardan conference?
How can investors access REGENXBIO's (RGNX) presentation at the Chardan conference?
How long will the replay of REGENXBIO's (RGNX) Chardan conference presentation be available?
